Based on the provided data for Renin-Angiotensin System medicine sales in Austria, the value stood at 125 million Euros in 2023. Forecasts for 2024 to 2028 show a steady decline in sales from 121.9 million Euros in 2024 to 109.6 million Euros in 2028. The year-on-year variation percentages showcase a consistent decrease of approximately 2.7% per year from 2024 to 2028. Considering the Compound Annual Growth Rate (CAGR) over the last five years, the average annual decline is around 3%. This steady downturn indicates changing market dynamics or shifts in treatment protocols.
Future trends to watch for:
- The impact of generic medication on market values.
- Advances in alternative treatments reducing the reliance on Renin-Angiotensin System medicines.
- Healthcare policy changes and reimbursement rates affecting overall sales volume and value.
